Obesity Week 2026 at a glance
Developments in obesity therapeutics are extending competition beyond weight-loss efficacy toward body composition, treatment durability and personalised care. This Obesity Week 2026 preview examines the scientific themes, competitor activities and emerging technologies that could influence the obesity market, shape the competitive landscape and inform future treatment strategies.
📅 Build your schedule around the sessions that matter most.
📥 Download the Obesity week 2026_Preview_by_LucidQuest
Key Scientific Themes to Watch at Obesity Week 2026
Body Composition and Treatment Differentiation
Lean-mass preservation, visceral fat and the INHBE–Activin E pathway may reshape how obesity treatment success is assessed.
Emerging Mechanisms in the Obesity Drug Pipeline
Amylin, multi-receptor agonists and targets including ALK7, GPR75 and MC4R expand the early-stage therapeutic landscape.
Treatment Durability and Long-Term Maintenance
GLP-1 discontinuation, weight regain and long-term maintenance strategies will feature alongside efficacy.
Access and Care Delivery
Insurance coverage, paediatric care, MASLD and integration with bariatric surgery remain strategic priorities.
Competitor and Industry Signals at Obesity Week 2026
Wave Life Sciences: Body Composition as a Potential Differentiator
Body composition and INHBE–Activin E as potential differentiators in obesity treatment.
Novo Nordisk: Amylin and Paediatric Obesity Care
Amylin biology and comprehensive paediatric obesity care.
Eli Lilly: Obesity Therapeutics and Multidisciplinary Care
Zepbound, Foundayo and multidisciplinary care, with retatrutide featuring in preclinical comparative research.
Amgen and Boehringer Ingelheim: Treatment Durability and Metabolic Targets
Treatment discontinuation, MASLD and glucagon biology.
Rhythm Pharmaceuticals: Diagnostic Recognition in Hypothalamic Obesity
Diagnostic recognition of acquired hypothalamic obesity.
Artificial Intelligence and Machine Learning at Obesity Week 2026
AI-Driven Drug Discovery
AI foundation models and cryo-EM will feature in amylin receptor research, alongside AI-guided adipose-targeted delivery.
Predictive Analytics for Obesity Treatment
ML models will explore semaglutide response, weight-regain risk and visceral adipose tissue.
Digital Health and Metabolic Monitoring
AI-powered feedback, wearables and virtual care will be examined for patient engagement and metabolic monitoring.
What We Are Watching After Obesity Week 2026
-
Whether body composition becomes a more established measure of treatment success.
-
Whether emerging mechanisms and AI-enabled tools demonstrate clinically actionable value.
-
Whether evolving coverage and maintenance strategies improve real-world treatment continuity.
Download the Obesity Week 2026 Preview Report
Download LucidQuest’s preview report for a closer look at the scientific developments, competitive signals and strategic questions surrounding Obesity Week 2026.
📅 Build your schedule around the sessions that matter most.
📥 Download the Obesity week 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
